# Innate Pharma SA: overview IPHA · Nasdaq · CIK 1598599 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ipha.md) · [Financials](/companies/ipha/financials.md) · [Filings](/companies/ipha/filings.md) · [Insiders](/companies/ipha/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [24.7](/filings/0001598599-24-000020.md) | [57.7](/filings/0001598599-25-000042.md) | [61.6](/filings/0001598599-26-000005.md) | [20.1](/filings/0001598599-26-000005.md) | [9.0](/filings/0001598599-26-000005.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(193.6%)](/filings/0001598599-24-000020.md) | [(99.6%)](/filings/0001598599-25-000042.md) | [(20.6%)](/filings/0001598599-26-000005.md) | [(256.3%)](/filings/0001598599-26-000005.md) | [(599.8%)](/filings/0001598599-26-000005.md) | | Net margin | % | [(213.8%)](/filings/0001598599-24-000020.md) | [(100.7%)](/filings/0001598599-25-000042.md) | [(12.3%)](/filings/0001598599-26-000005.md) | [(245.9%)](/filings/0001598599-26-000005.md) | [(546.1%)](/filings/0001598599-26-000005.md) | | Diluted EPS | $ per share | [(0.66)](/filings/0001598599-24-000020.md) | [(0.73)](/filings/0001598599-25-000042.md) | [(0.09)](/filings/0001598599-26-000005.md) | [(0.61)](/filings/0001598599-26-000005.md) | [(0.55)](/filings/0001598599-26-000005.md) | | Free cash flow | $m | [(59.4)](/filings/0001598599-24-000020.md) | [(19.7)](/filings/0001598599-25-000042.md) | [(32.9)](/filings/0001598599-26-000005.md) | [(7.3)](/filings/0001598599-26-000005.md) | [(52.9)](/filings/0001598599-26-000005.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ipha/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Lion Point Capital, LP](/funds/1643354.md) | 2026-06-30 | $149.3k | 81,151 | | Unchanged | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $80.1k | 43,524 | | Unchanged | | [SmartHarvest Portfolios, LLC](/funds/2066604.md) | 2026-06-30 | $43.7k | 23,750 | | New +23,750 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $27.8k | 15,130 | | New +15,130 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $22.9k | 12,441 | | New +12,441 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $19.0k | 10,310 | | Reduced −33,055 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $8.7k | 4,719 | | Reduced −15 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $2.5k | 1,363 | | Added +502 | | [Farther Finance Advisors, LLC](/funds/1992825.md) | 2026-06-30 | $38 | 21 | | Added +11 | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $17 | 9 | | Reduced −231 | ## Recent filings [All 326 filings](/companies/ipha/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 07:13 ET | [6-K](/filings/0001628280-26-067408.md) | Report of a foreign private issuer, period 2026-10-27 | 0001628280-26-067408 | | 2026-10-21 | 06:08 ET | [6-K](/filings/0001628280-26-066591.md) | Report of a foreign private issuer, period 2026-10-21 | 0001628280-26-066591 | | 2026-10-20 | 06:09 ET | [6-K](/filings/0001628280-26-066382.md) | Report of a foreign private issuer, period 2026-10-20 | 0001628280-26-066382 | | 2026-09-17 | 06:33 ET | [6-K](/filings/0001628280-26-062360.md) | Report of a foreign private issuer, period 2026-09-17 | 0001628280-26-062360 | | 2026-09-17 | 06:30 ET | [6-K](/filings/0001598599-26-000010.md) | Report of a foreign private issuer, period 2026-06-30 | 0001598599-26-000010 | | 2026-09-17 | 06:21 ET | [6-K](/filings/0001628280-26-062357.md) | Report of a foreign private issuer, period 2026-09-16 | 0001628280-26-062357 | | 2026-09-10 | 06:28 ET | [6-K](/filings/0001628280-26-061214.md) | Report of a foreign private issuer, period 2026-09-10 | 0001628280-26-061214 | | 2026-09-02 | 06:56 ET | [6-K](/filings/0001628280-26-059963.md) | Report of a foreign private issuer, period 2026-09-02 | 0001628280-26-059963 | | 2026-08-19 | 16:02 ET | [6-K](/filings/0001628280-26-057935.md) | Report of a foreign private issuer, period 2026-08-19 | 0001628280-26-057935 | | 2026-08-14 | 06:00 ET | [6-K](/filings/0001628280-26-056913.md) | Report of a foreign private issuer, period 2026-08-14 | 0001628280-26-056913 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001598599-26-000005.md), filed Apr 1, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1598599 - Tickers: IPHA, IPHYF - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: I0 - Filer category: Accelerated filer Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:14 ET. No prices; not investment advice.